Cargando…

Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an innovative form of taxane that has superior antitumor effects; however, the safety profile between nab-paclitaxel and traditional taxanes remains controversial. OBJECTIVE: To determine the burden of adverse events (AEs) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Fei, Liu, Jiaxuan, Shen, Xin, Wang, Zijing, Li, Qiao, Li, Guohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237853/ https://www.ncbi.nlm.nih.gov/pubmed/34963337 http://dx.doi.org/10.1177/10600280211058385

Ejemplares similares

Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer
por: TAKASHIMA, SEIKI, et al.
Publicado: (2015)

Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis
por: Lee, Hwaryeon, et al.
Publicado: (2020)

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
por: Naganuma, Misa, et al.
Publicado: (2019)

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
por: Fabi, Alessandra, et al.
Publicado: (2015)

Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis
por: Li, Bingxue, et al.
Publicado: (2021)

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
por: Cirauqui, Beatriz Cirauqui, et al.
Publicado: (2014)

Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis
por: Li, Bing-Xue, et al.
Publicado: (2021)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

Albumin-bound paclitaxel in solid tumors: clinical development and future directions
por: Kundranda, Madappa N, et al.
Publicado: (2015)

Nanoparticle Albumin‑Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
por: Gangannapalle, Mahesh, et al.
Publicado: (2023)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
por: Palumbo, Raffaella, et al.
Publicado: (2015)

Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system
por: Wang, Yuwei, et al.
Publicado: (2023)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors
por: Cohen, Adam L., et al.
Publicado: (2016)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
por: Zhang, Changhua, et al.
Publicado: (2013)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells
por: Vallo, Stefan, et al.
Publicado: (2017)

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
por: Wang, Hai-ying, et al.
Publicado: (2016)

S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma
por: Xia, Yu, et al.
Publicado: (2022)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports
por: KIMURA, KOSEI, et al.
Publicado: (2013)

Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis
por: Li, Xin, et al.
Publicado: (2019)

Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer
por: Guo, Qie, et al.
Publicado: (2022)

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
por: Xing, Puyuan, et al.
Publicado: (2017)

Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
por: Huang, Yan, et al.
Publicado: (2016)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy
por: Abaza, Yasmin M., et al.
Publicado: (2014)

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma
por: Tsuji, Takahiro, et al.
Publicado: (2015)

Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
por: Zong, Yu, et al.
Publicado: (2017)

Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes
por: Motegi, Sei-ichiro, et al.
Publicado: (2019)

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer
por: Yamane, Hiroaki, et al.
Publicado: (2023)

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
por: Di Costanzo, Francesco, et al.
Publicado: (2009)

Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel
por: Vigata, Margaux, et al.
Publicado: (2020)

Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas
por: Gould, Andrew, et al.
Publicado: (2021)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Shi, Yan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_joetcklhkmv8oh9h83f8cf7ruf